Sartorius Stedim Biotech completed the acquirsition of Novasep‘s chromatography process equipment division. Novasep’s division expects to generated sales of approximately €40 million in 2020 with double-digit profit margins. The company employs approximately 100 people, with the majority working at its Pompey site in northern France, as well as the U.S., China and India. Financial details were not disclosed.

Novasep’s chromatography unit comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin. Since 2018, the companies have been collaborating in the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively and that is expected to launch soon.

The acquisition is expected to generate additional non-organic sales revenue growth of around 1 percentage point in 2022. Sartorius has updated its sales revenue forecast for the current year: Consolidated sales revenue is now expected to increase by about 15 percent to 19 percent (previously about 14 percent to 18 percent), with non-organic growth from acquisitions projected to contribute about 2 percentage points (previously about 1 percentage point).